Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Timing

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Jan 12, 2021 10:53am

105 Views

Post# 32275589

RE:Timing

Unfortunately, there's no requirement it be divulged unless their counsel believes it is "material" as to who it may be. So if the company announces something, it would have to be either an industry partner or meaninngful investor who also allows them to disclose this as some institutions are not allowed to discuss holdings until filed in quarterly reports. Otherwise, if any buyers are over the disclosure limits, they will file those quarterly reports, so March time frame. If no one is over the disclosure limits of either US or Canada, there is no requirement.

My guess is between lose-lipped brokers and the like, there will be enough scuttlebu.t.t. to figure it out one way or the other within the next few weeks.